Leerink raised the firm’s price target on Janux Therapeutics (JANX) to $91 from $79 and keeps an Outperform rating on the shares. The firm says Janux delivered with updated Phase 1 dose escalation data for lead candidate JANX007, exceeding its optimistic in-going expectations. JANX007 demonstrated impressive, best-in-disease PSA efficacy and a best-in-class, differentiated safety profile across all evaluable patients with 3L+ metastatic castration-resistant prostate cancer, Leerink adds.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics price target raised to $200 from $100 at Cantor Fitzgerald
- Janux Therapeutics price target raised to $70 from $63 at H.C. Wainwright
- Closing Bell Movers: Zscaler down 8% despite earnings beat
- Janux Therapeutics Reports Promising JANX007 Trial Results
- Janux says emerging JANX007 data demonstrates ‘substantial clinical activity’